Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Not Applicable

Recruiting

• Conditions: Lymphoma; Large-cell Lymphoma; Large B-cell Lymphoma; Mediastinal B-Cell Diffuse Large Cell Lymphoma; Lymphoma, B-Cell; DLBCL - Diffuse Large B Cell Lymphoma
• Interventions: Behavioral: Hematolo-GIST Training; Behavioral: Participants Appointment

• Registration Number: NCT05940272
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-07-03
• Study First Submitted: 2023-07-03
• Study First Submitted QC: 2023-07-03
• Study First Posted: 2023-07-11
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-06
• Last Update Posted: 2025-01-07
• Primary Completion: 2028-07-03
• Study Completion: 2028-07-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Hematologists

• Currently a hemotologic oncologist providing care to patients with DLBCL

Patients

• Per medical record, is being treated by a hematologic oncologist participating in this study

• Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma

• Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or autologous stem cell transplant (ASCT)

• Self-identify as Black and/or White

• Per medical record, 18 years of age or older

• Per self-report, fluent in English** ** Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

  1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  2. What is your preferred language for healthcare? (must respond English)

Exclusion Criteria

Hematologists

• Per self-report, planning to leave the cancer center in the next 12 months

Patients

• Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
• Per research staff judgment and/or self-report, too ill or weak to complete study procedures
• Per medical record or self-report, receiving hospice care at the time of enrollment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Hematologists	Hematolo-GIST Training	-
Patients	Participants Appointment	-

Primary Outcome Measures

Name	Time	Method
Feasibility of the Hematolo-GIST intervention among hematologists and participants	Up to 1 year	Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach

Trial Locations

Locations (2)

Memorial Sloan Kettering Cancer Center (All protocol activities); 🇺🇸 New York, New York, United States

NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only); 🇺🇸 New York, New York, United States